Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 5/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.46 |
| ▸ | IGF2R | P11717 | 1/20 | 0.44 |
| ▸ | FGF1 | P05230 | 1/20 | 0.43 |
| ▸ | FGF2 | P09038 | 1/20 | 0.43 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SELL | P14151 | 1/20 | 0.41 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29632945 | 0.89 | SELE (0.50) | SELEAMY1AIGF2RFGF1FGF2 | |
| SCHEMBL22026382 | 0.87 | IGF2R (0.48) | SELEAMY1AIGF2RFGF1FGF2 | |
| SCHEMBL18412621 | 0.87 | SELE (0.43) | SELEAMY1AIGF2RFGF1FGF2 | |
| SCHEMBL15948364 | 0.86 | CD209 (0.50) | SELEIGF2RFGF1FGF2VEGFA | |
| SCHEMBL15948436 | 0.86 | LGALS8 (0.47) | SELEAMY1AFGF1FGF2VEGFA | |
| SCHEMBL10014356 | 0.86 | LGALS8 (0.52) | IGF2RFGF1FGF2VEGFAHPSE | |
| SCHEMBL18122156 | 0.85 | IGF2R (0.48) | IGF2RFGF1FGF2VEGFAHPSE | |
| SCHEMBL10014361 | 0.85 | LGALS8 (0.45) | SELEAMY1AIGF2RFGF1FGF2 | |
| SCHEMBL17938769 | 0.85 | AMY1A (0.55) | SELEAMY1AMEN1KMT2ASTAT3 | |
| SCHEMBL26032277 | 0.85 | AMY1A (0.54) | SELEAMY1AIGF2RFGF1FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9629865-B2 | Modified saponins for the treatment of fungal infections | THE BROAD INSTITUTE, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160228465-A1 | Modified Saponins For the Treatment of Fungal Infections | NIH - DEITR | 2016-08-11 | — | — | US | disclosed |
| US-9320751-B2 | Modified saponins for the treatment of fungal infections | THE GENERAL HOSPITAL CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150182544-A1 | Modified Saponins for the Treatment of Fungal Infections | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2015-07-02 | — | — | US | disclosed |
| US-8987217-B2 | Modified saponins for the treatment of fungal infections | THE GENERAL HOSPITAL CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182544-A1 | Modified Saponins for the Treatment of Fungal Infections | ERG28, TREH, MANBA | SELE 2604/4885AMY1A 227/4885IGF2R 2541/4885 |
| US-20160228465-A1 | Modified Saponins For the Treatment of Fungal Infections | ERG28, TREH, MANBA | SELE 2604/4885AMY1A 227/4885IGF2R 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.